FBR Capital Initiates Biocryst Pharmaceuticals With Outperform

Analysts at FBR Capital initiated coverage on

with a Outperform rating. The target price for Biocryst Pharmaceuticals is set to $18. Biocryst Pharmaceuticals shares have gained 11.85 percent over the past 52 weeks, while the S&P 500 index has surged 11.75 percent in the same period. Biocryst Pharmaceuticals' shares rose 6.90 percent to $11.00 in pre-market trading.